Tessera Defense and Homeland Security Inc

NYSE:HLSQHealthcare · Biotechnology

Mkt Cap$5.54M

Float10.01M

Shares O/S26M

Inst Own0.3%

SI3.0%

Dilution

-18.20%$0.2131

AH Close$0.2113-0.84%vs close

Mkt Cap$5.54M

Float10.01M

O/S26M

Inst Own0.3%

SI3.0%

Dilution

NYSE:HLSQ$0.2131-18.20%

MCap$5.54M

Float10.01M

O/S26M

SI3.0%

Inst Own0.3%

Dilution

Historical Data

Date	Open	High	Low	Close	Volume

Key Metrics

Market Cap$5.54M

Enterprise Value--

P/E Ratio--

Est. Net Cash/Share--

Institutional Ownership0.27%

based on 26.00M shares outstanding

SectorHealthcare

IndustryBiotechnology

ExchangeNYSE American

Country

IPO DateSep 11, 2026

Shares Outstanding26.00M

Float10.01M

SEC Float (non-affiliate)25.98M

Company Overview

Tessera Defense & Homeland Security, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis.

Its product pipelines include BX004 and BX005, which are treatments for cystic fibrosis and atopic dermatitis respectively.

The company was founded in March 2015 and is headquartered in Dover, DE.

Leadership

David Rokach

CFO, Principal Financial Officer & Principal Accounting Officer

Guy Arieli

Director

Liat Bidas

Director

Michael Oster

CEO & Director

Employees

Country

Sector

Healthcare

Website

biomx.com

Analyst Coverage

No analyst coverage for this companyNo ratings, price targets, or covering firms on file.

Insider Trades

No insider transactions for this companyForeign private issuers and non-reporting entities don't file Form 4/5.

Shareholders

0.3%

Institutional

(9)

0.8%

Insiderⓘ

(5)

3.7%

5%+ Owners

(6)

of which 0.8% rests on schedules older than 24 months (1 holder)

95.2%

Unattributed (incl. retail)ⓘ

Institutional0.3%

Insider0.8%

5%+ Beneficial3.7%

Unattributed (incl. retail)95.2%

Top Shareholders

Name	Shares	%	Source
Ram Naim · joint filing· may incl. warrants· filed Oct 2026	477.6K	1.8%	13D
Johnson & Johnson · may incl. warrants· stale · filed Feb 2024	211.3K	0.8%	13G
Cystic Fibrosis Foundation 10% Owner	178.8K	0.7%	FORM 4
Star 26 Capital Inc. · joint filing· may incl. warrants· filed Sep 2026	156.8K	0.6%	13D
Nantahala Capital Management, LLC	63.5K	0.2%	13F
Mandragola Ltd. · joint filing· may incl. warrants· filed Oct 2026	55.4K	0.2%	13G
Deerfield Management Company, L.P. · joint filing· may incl. warrants· filed Jun 2026	53.3K	0.2%	13D
Solomon Jonathan Eitan Chief Executive Officer, Director	12.7K	0.0%	FORM 4
Telmina Limited · joint filing· may incl. warrants· filed May 2026	8.3K	0.0%	13G
Bassan Merav Chief Development Officer	8.0K	0.0%	FORM 4